Freemont Management S.A. Purchases New Stake in Amneal Pharmaceuticals, Inc. $AMRX

Freemont Management S.A. purchased a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 320,000 shares of the company’s stock, valued at approximately $3,978,000.

Other large investors have also added to or reduced their stakes in the company. Rubric Capital Management LP grew its stake in shares of Amneal Pharmaceuticals by 5.3% in the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock worth $123,473,000 after purchasing an additional 624,609 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Amneal Pharmaceuticals by 3.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 5,609,040 shares of the company’s stock valued at $70,681,000 after purchasing an additional 177,906 shares during the last quarter. Morgan Stanley raised its position in Amneal Pharmaceuticals by 37.5% during the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock valued at $60,708,000 after purchasing an additional 1,315,018 shares during the last quarter. Nantahala Capital Management LLC lifted its holdings in Amneal Pharmaceuticals by 14.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock worth $35,333,000 after buying an additional 558,877 shares during the period. Finally, State Street Corp lifted its holdings in Amneal Pharmaceuticals by 3.4% in the 4th quarter. State Street Corp now owns 4,110,410 shares of the company’s stock worth $51,791,000 after buying an additional 136,662 shares during the period. Institutional investors own 31.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on AMRX shares. Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Barclays raised their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Weiss Ratings cut shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. UBS Group boosted their price objective on shares of Amneal Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.60.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the transaction, the director owned 93,660 shares in the company, valued at $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 17.30% of the stock is owned by insiders.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ:AMRX opened at $17.85 on Friday. Amneal Pharmaceuticals, Inc. has a 1 year low of $7.66 and a 1 year high of $18.39. The company has a market cap of $5.69 billion, a P/E ratio of 46.97 and a beta of 1.26. The stock’s fifty day moving average price is $15.05 and its 200-day moving average price is $13.89.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The business had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. On average, sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.